Senti Bio Sets October 8 Vote on Celadon Merger, Reverse Split, and Nasdaq Compliance
SNTI sits 18% above its 52-week low of $0.29 on elevated volume (2.9× avg).
Summary
Senti Bio's definitive proxy sets an October 8 vote on the Celadon merger, a reverse stock split, and Nasdaq compliance. Management's liquidation analysis values the stock at $0.00, making the merger the only path to value.
Key Events · M&A and Partnerships · SNTI
-
October 8 Vote on Celadon Merger
The definitive proxy sets the annual meeting for October 8, 2026, to vote on the Celadon-led merger spinning off SENTI-202 for CVRs worth up to $60M in milestone payments.
-
Reverse Stock Split Proposal
Stockholders will vote on a 1-for-20 to 1-for-50 reverse stock split to regain Nasdaq compliance after receiving minimum bid price and stockholders' equity deficiency notices on August 27, 2026.
-
Liquidation Value at $0.00
Management's liquidation analysis shows negative equity value of $23.3M to $27.6M, implying $0.00 per share for common stockholders if the merger fails.
-
Nasdaq Delisting Risk
The company received two delisting notices on August 27, 2026: minimum bid price below $1.00 for 30 consecutive days and stockholders' deficit of $3.4M vs. $2.5M requirement.
Analysis · SNTI · Life Sciences
The definitive proxy locks in the October 8, 2026 shareholder vote on the Celadon-led merger that spins off SENTI-202 for CVRs worth up to $60M. It also seeks approval for a 1-for-20 to 1-for-50 reverse stock split to regain Nasdaq compliance after receiving two delisting notices on August 27, 2026. Management's own liquidation analysis values the stock at $0.00 per share, making the merger the only realistic path to any value for public shareholders. The deal requires both majority-of-outstanding and majority-of-minority approval, with Celadon and insiders holding 32.6% already committed to vote in favor.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 37.9% of the 895 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.87%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SNTI was trading at $0.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.7M. The 52-week trading range was $0.29 to $2.88. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.